BIOD-123 — Competitive Intelligence Brief

BIOD-123 (BIOD-123) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rapid-acting insulin. Area: Diabetes.

phase 2 Rapid-acting insulin Insulin receptor Diabetes Small molecule

Target snapshot

BIOD-123 (BIOD-123) — Biodel. BIOD-123 is a rapid-acting insulin formulation designed to improve postprandial glucose control in diabetes patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BIOD-123 TARGET	BIOD-123	Biodel	phase 2	Rapid-acting insulin	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rapid-acting insulin class)

1. Biodel · 4 drugs in this class
2. Informed Data Systems, Inc. · 1 drug in this class
3. Novo Nordisk A/S · 1 drug in this class
4. Pfizer · 1 drug in this class
5. University of Nottingham · 1 drug in this class